Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: Evidence from the ESME real-world database

Using data from the French Épidémio-Stratégie Médico-Economique database, researchers analyzed the individual-level association between real-world progression-free survival (PFS) and overall survival (OS) for first-line treatments in patients with metastatic breast cancer. For patients with HR+/HER2 + metastatic breast cancer, the real-world PFS/OS association was weak to strong, with coefficients ranging from 0.33-0.43 for monotherapy and from 0.67-0.78 for combined therapies.